MacroGenics Inc. [NASDAQ: MGNX] jumped around 3.7 points on Thursday, while shares priced at $32.90 at the close of the session, up 12.67%. The company report on February 26, 2021 that MacroGenics to Participate in Upcoming Investor Conferences.
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that the Company’s management will participate in the following investor conferences in March:.
MacroGenics Inc. stock is now 43.92% up from its year-to-date (YTD) trading value. MGNX Stock saw the intraday high of $33.25 and lowest of $29.7798 per share. The company’s 52-week high price is 33.11, which means current price is +81.17% above from all time high which was touched on 03/25/21.
Compared to the average trading volume of 827.09K shares, MGNX reached a trading volume of 1170917 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about MacroGenics Inc. [MGNX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MGNX shares is $33.70 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MGNX stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Barclays have made an estimate for MacroGenics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on March 12, 2021. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on December 22, 2020, representing the official price target for MacroGenics Inc. stock. Previously, the target price had yet another raise from $25 to $26, while Citigroup kept a Neutral rating on MGNX stock.
The Average True Range (ATR) for MacroGenics Inc. is set at 2.13, with the Price to Sales ratio for MGNX stock in the period of the last 12 months amounting to 16.91. The Price to Book ratio for the last quarter was 6.25, with the Price to Cash per share for the same quarter was set at 5.05.
How has MGNX stock performed recently?
MacroGenics Inc. [MGNX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.63. With this latest performance, MGNX shares gained by 56.15% in over the last four-week period, additionally plugging by 33.09% over the last 6 months – not to mention a rise of 488.55% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MGNX stock in for the last two-week period is set at 66.20, with the RSI for the last a single of trading hit 66.23, and the three-weeks RSI is set at 65.15 for MacroGenics Inc. [MGNX]. The present Moving Average for the last 50 days of trading for this stock 24.12, while it was recorded at 31.23 for the last single week of trading, and 24.79 for the last 200 days.
MacroGenics Inc. [MGNX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and MacroGenics Inc. [MGNX] shares currently have an operating margin of -124.96. MacroGenics Inc.’s Net Margin is presently recorded at -123.70.
Return on Total Capital for MGNX is now -44.70, given the latest momentum, and Return on Invested Capital for the company is -44.79. Return on Equity for this stock declined to -49.28, with Return on Assets sitting at -37.54. When it comes to the capital structure of this company, MacroGenics Inc. [MGNX] has a Total Debt to Total Equity ratio set at 9.88. Additionally, MGNX Total Debt to Total Capital is recorded at 9.00, with Total Debt to Total Assets ending up at 7.72. Long-Term Debt to Equity for the company is recorded at 8.54, with the Long-Term Debt to Total Capital now at 7.77.
Reflecting on the efficiency of the workforce at the company, MacroGenics Inc. [MGNX] managed to generate an average of -$350,646 per employee. Receivables Turnover for the company is 5.86 with a Total Asset Turnover recorded at a value of 0.30.MacroGenics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.20 and a Current Ratio set at 6.20.
Earnings analysis for MacroGenics Inc. [MGNX]
With the latest financial reports released by the company, MacroGenics Inc. posted -0.91/share EPS, while the average EPS was predicted by analysts to be reported at -1.02/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 10.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MGNX.
Insider trade positions for MacroGenics Inc. [MGNX]
There are presently around $1,769 million, or 96.90% of MGNX stock, in the hands of institutional investors. The top three institutional holders of MGNX stocks are: BELLEVUE GROUP AG with ownership of 5,904,517, which is approximately 11.782% of the company’s market cap and around 0.40% of the total institutional ownership; BLACKROCK INC., holding 5,104,831 shares of the stock with an approximate value of $167.95 million in MGNX stocks shares; and RA CAPITAL MANAGEMENT, L.P., currently with $143.94 million in MGNX stock with ownership of nearly 0% of the company’s market capitalization.
Positions in MacroGenics Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 86 institutional holders increased their position in MacroGenics Inc. [NASDAQ:MGNX] by around 6,486,342 shares. Additionally, 50 investors decreased positions by around 6,601,779 shares, while 24 investors held positions by with 40,693,168 shares. The mentioned changes placed institutional holdings at 53,781,289 shares, according to the latest SEC report filing. MGNX stock had 22 new institutional investments in for a total of 1,189,797 shares, while 15 institutional investors sold positions of 493,373 shares during the same period.